Perennial Malaria Chemoprevention in the Malaria Vaccine Era

Malaria remains a major cause of pediatric deaths and morbidity in Africa. An affordable malaria vaccine, R21, is being deployed in Uganda and other African countries with high malaria transmission, but efficacy is incomplete and wanes rapidly, and R21 does not provide protection until infants complete the primary vaccination series, or \~9 months of age. The goal of this study is to see whether combining R21 vaccination with two novel perennial malaria chemoprevention regimens can enhance protection against malaria compared with R21 alone. This study will take place at Masafu General Hospital (MGH) in Busia District, a rural area in Southeastern Uganda bordering Lake Victoria.

NCT Number	NCT07322068
Lead Sponsor	Stanford University Collaborators: University of California, San Francisco, Infectious Diseases Research Collaboration, Uganda, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions	Malaria, Falciparum
Enrollment	1,290 participants
Start Date	2026-09
Primary Completion	2033-06 (estimated)
Study Completion	2033-06 (estimated)
Updated on ClinicalTrials.gov	2026-01-07